Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
A greatly expanded understanding of the biology of endogenous erythropoietin (EPO) has emerged since the early 1990s. Originally viewed as the renal hormone dedicated to erythrocyte production, it is now clear that EPO is produced locally by many other tissues in response to physical or metabolic stress. In its autocrine-paracrine roles, EPO mediates preconditioning (ischemic tolerance) and specifically limits the destructive potential of tumor necrosis factor alpha and other proinflammatory cytokines in the brain, heart, kidney, and other tissues. As local production of EPO is generally suppressed following injury, administration of exogenous EPO has been a successful therapeutic approach in preclinical and clinical studies, for example, following ischemia-reperfusion and toxin-induced renal injuries, and in human stroke. The therapeutic time window of tissue protection by EPO is typically very wide in experimental models, showing effectiveness when administered before, during, or after an insult and raising optimism for a high clinical potential. Although there is progress in understanding the signaling pathways responsible for EPO's tissue-protective actions that are similar to, but not as redundant as, those employed for erythrocyte maturation, much work remains to be carried out. Experimental observations also suggest the existence of EPO receptor (EPOR) isoforms mediating EPO's diverse biological activities and have identified a tissue-protective receptor complex consisting of the EPOR and the beta common receptor (CD131) subunit that is also employed by granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5. Successfully engineered analogues of EPO that selectively activate tissue protection without stimulating hematopoiesis confirm the concept of a tissue-protective receptor and have significant potential utility in the investigational and therapeutic arenas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [2152]
Citations
Cites
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402
Self-citationErythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,028
Self-citationErythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
Sirén, A.-L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051606598 · Cited by 1,019
Self-citationBrines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., Latini, R., Xie, Q.-W., Smart, J., Su-Rick, C.-J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406491101 · Cited by 656
Self-citationErythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.
Anagnostou, A., Lee, E. S., Kessimian, N., Levinson, R., & Steiner, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5978 · Cited by 569
Erythropoietin Gene Expression in Human, Monkey and Murine Brain
Marti, H. H., Wenger, R. H., Rivas, L. A., Straumann, U., Oigicaylioglu, M., Henn, V., Yonekawa, Y., Bauer, C., & Gassmann, M. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01252.x · Cited by 552
Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., Viviani, B., Marinovich, M., Cerami, A., Coleman, T. R., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021067 · Cited by 527
Self-citationEmerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
Self-citationErythropoietin regulates endothelial progenitor cells
Bahlmann, F. H., de Groot, K., Spandau, J.-M., Landry, A. L., Hertel, B., Duckert, T., Boehm, S. M., Menne, J., Haller, H., & Fliser, D. (2004) · Blood · doi:10.1182/blood-2003-04-1284 · Cited by 504
Localization of specific erythropoietin binding sites in defined areas of the mouse brain.
Digicaylioglu, M., Bichet, S., Marti, H. H., Wenger, R. H., Rivas, L. A., Bauer, C., & Gassmann, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3717 · Cited by 474
Cited by
Regulation of erythropoietin production
Jelkmann, W. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.195057 · Cited by 599
“A role has been proposed for Epo as a cytoprotective agent for several non-haematopoietic tissues, including the brain, the heart, blood vessels and the kidneys (Brines & Cerami, 2006).”
BackgroundKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“[1971] Brines, M.”
Efficacy and Safety of Epoetin Alfa in Critically Ill Patients
Corwin, H. L., Gettinger, A., Fabian, T. C., May, A., Pearl, R. G., Heard, S., An, R., Bowers, P. J., Burton, P., Klausner, M. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071533 · Cited by 545
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
Brines, M., Patel, N. S. A., Villa, P., Brines, C., Mennini, T., De Paola, M., Erbayraktar, Z., Erbayraktar, S., Sepodes, B., Thiemermann, C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805594105 · Cited by 319
“Brines M, Cerami A (2006) Discovering erythropoietin’s extra-hematopoietic functions: Biology and clinical promise.”
BackgroundInfluentialSelf-citationChatterjee, P. K. (2007) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-007-0183-5 · Cited by 222
“…evidence that EPO, which is used clinically as recombinant human EPO (rHuEPO) for the treatment of anemia associated with ESRF and cancer chemotherapy, possesses pleiotropic properties that are separate from its long-recognized hematopoietic actions (Brines and Cerami 2006; Fliser et al. 2006a).”
Background
Metadata
- Authors
- Brines, M., & Cerami, A.
- Corresponding author
- Brines, M.
- ORCID
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 70
- Issue
- 2
- Pages
- 246-250
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2160549233
- Cited by
- 290
- References
- 27
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 16 · 2016: 16 · 2015: 9 · 2014: 10 · 2013: 23 · 2012: 19
- FWCI
- 18.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3446 d)
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heme Oxygenase-1 and Carbon Monoxide
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- erythropoietin, ischemic preconditioning, ischemic tolerance, tissue protection, TNF-α, inflammatory cytokines, kidney injury, ischemia-reperfusion injury, stroke, CD131, autocrine and paracrine signaling
- MeSH terms
- Animals, Endothelium, Vascular, Erythropoietin, Humans, Kidney, Kidney Diseases, Reperfusion Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. https://app.cochat.ai/papers/10.1038/sj.ki.5001546
- The paper
- Brines, M., & Cerami, A. (2006). Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney International. https://doi.org/10.1038/sj.ki.5001546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.